CBP 307

Drug Profile

CBP 307

Alternative Names: CBP-307

Latest Information Update: 26 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Suzhou Connect Biopharmaceuticals
  • Class Antipsoriatics
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Autoimmune disorders
  • Preclinical Crohn's disease; Ulcerative colitis

Most Recent Events

  • 24 Apr 2018 Suzhou Connect Biopharmaceuticals plans a phase II trial for Ulcerative colitis and Crohn's disease in China in the first half of 2018 (Suzhou Connect Biopharmaceuticals Pipeline, April 2018)
  • 20 Nov 2014 CBP 307 is available for licensing in (excluding China) as of 06 Nov 2014. http://www.connectbiopharm.com/
  • 01 Nov 2014 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top